Press release
September 30, 2026
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Celcuity Inc. (CELC)
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K